How much revenue does Zydus Lifesciences make?

Zydus Lifesciences reported 225.74 billion INR in revenue for fiscal year 2025, up 18.7% from 190.22 billion INR in fiscal year 2024. In Q1 2026 revenue was 64.67 billion INR.

What is Zydus Lifesciences's largest business segment?

Pharmaceuticals, with 205.44 billion INR or 88% of segment revenue in fiscal year 2025. Next: Consumer Products (12%).

Where does Zydus Lifesciences make most of its revenue?

United States: 48% of revenue by region in fiscal year 2025, followed by India (40%).

What companies are similar to Zydus Lifesciences?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Sun Pharmaceutical Industries Limited (SUNPHARMA.NS), Torrent Pharmaceuticals Limited (TORNTPHARM.NS), Cipla Limited (CIPLA.NS), Mankind Pharma Limited (MANKIND.NS).

Zydus Lifesciences Limited (ZYDUSLIFE.NS) Stock

About Zydus Lifesciences Limited

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Consumer Products, and Medical Technologies. The company offers active pharmaceutical ingredients, human and finished dosage formulations, generics, br...

At a glance

Zydus Lifesciences reported revenue of 225.74 billion INR for fiscal year 2025, up 18.7% from fiscal year 2024, and net income of 45.26 billion INR. In Q1 2026 (the quarter ended June 30, 2025) revenue was 64.67 billion INR, up 7.0% from a year before. Its largest business segment, Pharmaceuticals, brought in 88% of segment revenue in fiscal year 2025; United States was the largest region with 48%.

Figures from company filings; latest fiscal year ended March 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.